NCT02307604

SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial Access

Screening Platform of EORTC for Clinical Trials Access in Brain Tumors

• Status: Withdrawn
• Phase: —
• Study type: Observational
• Enrollment: 0 (actual)
• Sponsor: European Organisation for Research and Treatment of Cancer - EORTC · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The SPECTAbrain protocol describes a structure for screening patients with brain tumors to efficiently allocate eligible patients in relevant therapeutic biomarker-driven clinical trials. Efficiency is promoted through the creation of a clinical database of brain tumor patients and the respective human biological material biobank for molecular characterization. The main objectives are to: * Allocate patients to clinical trials according to the clinical characteristics and molecular profile of their tumor; * Identify or validate new molecularly defined subgroups of tumors; * Investigate the prevalence of novel biomarkers to plan future clinical trials; * Enable exploratory/future research; * Facilitate establishment of quality-assured and validated tests for Central Nervous System (CNS) tumor biomarkers;

Conditions

• Brain Neoplasms

Interventions

Type	Name	Description
GENETIC	Tumour markers testing

Timeline

• Start date: 2016-05-01
• Primary completion: 2019-01-01
• Completion: 2019-01-01
• First posted: 2014-12-04
• Last updated: 2019-06-24

Locations

2 sites across 1 country: France